activity could be beneficial in Parkinson's disease.1 The findings argue for developing brain-penetrating sirtuin 2 inhibitors.
Sirtuin 2 (SIRT2) is one of seven human sirtuins, a class of protein deacetylases with diverse roles in metabolic, inflammatory and autoimmune diseases. The best-studied member of the class is SIRT1, which first emerged in the 2000s when Harvard Medical School researchers showed that overexpressing or activating the target promoted disease resistance in multiple preclinical models of metabolic and neurological diseases.2
Based on those findings, Sirtris Pharmaceuticals Inc. was founded in 2004 to develop small molecule activators of sirtuins. The